Mission Possible: Working together to reshape the future of cancer care
Q&A with Greg Rossi, Senior VP, Head of Oncology Europe and Canada at AstraZeneca.
Health technology
Solid science in Europe: a farewell song?
Maintaining the highest standards is the only avenue to strengthen the EU health sector.
Europe has the tools to end Hepatitis C. It’s time to use them.
Global coverage of hepatitis C testing and treatment is “too low and stagnating” ― even in countries with advanced health care systems, says the WHO.
Political interference risks Slovak health technology authority’s independence [Advocacy Lab Content]
Political interference risks the independence of a leading Slovak health institute. Without formal discussion, the Slovak parliament rushed through an amendment changing leadership and funding criteria – the institute’s future now depends on the Consti…
Investment in European healthcare delivering innovation and improved patient care [Advocacy Lab Content]
Europe as a centre for health technology innovation has taken off in recent years with dozens of European companies leading the way in developing innovative solutions with the potential to raise the standard of healthcare and health systems globally.
Combination therapies offer hope to cancer patients – but we need to act now to ensure access
There is an urgent need to consider solutions to overcome complex access challenges to combination therapies — payers, policymakers and industry leaders must work together and act now to ensure access.
EU HTA: If we want faster access to cancer treatment for all Europeans, we need to get it right
In January 2025 the EU HTA Regulation will become reality. Let’s work together to ensure it facilitates faster patient access to new cancer treatments.
Strong intellectual property is critical to competitive edge
European intellectual property policies are weakening Europe’s competitive edge at the very moment that EU leaders have recognized the importance of restoring the region’s status as a global economic superpower.
Europe’s new Health Technology Assessment Regulation (HTAR) on the horizon [Advocacy Lab Content]
In early 2025, Europe will implement a uniform, pan-EU framework under the new Health Technology Assessment Regulation (HTAR), addressing disparities in evaluating the clinical value of pharmaceuticals and medical devices.
Inclusivity, transparency, delivery – navigating the EU’s new Health Technology Assessment Regulation (HTAR) [Advocacy Lab Content]
The EFPIA HTA Working Group’s Inka Heikkinen and James Ryan spoke with Euractiv’s Nicole Verbeeck, giving insights on moving towards a robust HTA system – one that serves patients, industry and progress in Europe or member states.
Ukraine’s health system is a symbol of resilience
“I marvel at the resilience of Ukraine’s health system, battered by war and yet still standing.”
EU funds first psychedelic study, in patients with incurable diseases
Magic mushrooms trial gets underway.
Speed is everything for patients: together we can bring medicines faster
Innovation only matters if it reaches patients.
Encouraging the spread of innovation for blood cancer in Europe
The EU’s Beating Cancer plan states that unless we take action, lives lost to cancer in Europe are set to increase by more than 24 percent by 2035, and it wants to see greater use of approved innovations to reduce preventable burdens on the healthcare system.
Let HIV communities lead
Ongoing HIV stigma hampers testing, treatment and prevention. Multilayered impacts necessitate community initiatives and the dismantling of discriminatory laws for effective collaboration, which are essential for achieving HIV elimination goals.
Seeing more than HIV: A person-centered approach to HIV care
There’s more to the experience of living with HIV than suppressing the virus. Listening, valuing and integrating patient voices in HIV care is critical to leave no one behind.
What’s in a name? Why unmet medical needs are riling the pharma industry
The EU wants to steer drug development to cover research gaps, but industry hates the idea.
What single market? Why Romanians get new medicines 2 years after Germans
Not all patients are equal when it comes to treatment with cutting-edge drugs.
Beware the beguiling Doctor Chatbot
A chatbot can provide convincing advice, but it can’t tell you where the advice came from, why it’s giving the advice or how its ethical balances have been considered.
Snus on the loose: How Swedish chewing tobacco keeps dividing Brussels
Lawmakers can’t agree whether snus is a potent alternative to cigarettes or a back door for Big Tobacco.
COVID-19: An evolving virus and ongoing presence
It’s key that we provide information, actionable steps and treatment options to help manage COVID-19 now and in the future.
A cure for HIV: When will Europe get there?
Presented by Gilead.